A CRISPR screen in endometrial cancer models identified genes and pathways that may shape progesterone resistance.
Evidence
This was a genome-wide screening and validation study in Ishikawa cells, a progestin-resistant cell model, and xenograft mouse models.
Caveat
The findings come from cell-line and mouse models, so they do not establish clinical predictors or treatment effects in patients.
Simplified
UNLABELLED: Endometrial carcinoma, a prevailing malignancy of the female reproductive system, exhibits escalating incidence and a trend towards early onset. Hormone therapy serves as a primary choice for fertility preservation and is also considered for advanced and recurrent cases. However, a considerable number of patients fail to respond favorably to progestin treatments. We employed technology to establish a comprehensive human genome library in the Ishikawa cell line. Subsequent exposure to medroxyprogesterone was followed by high-throughput sequencing, and differential gene expression and enrichment analyses were conducted using Model-based Analysis of Genome-wide CRISPR-Cas9 Knockout (MAGeCK) Robust Rank Aggregation (RRA) and MAGeCK Maximum-Likelihood Estimation (MLE) algorithms. An iterative data intersection approach was employed, utilizing sequenced data from progestin-resistant cell lines, to identify pivotal genes associated with . The top 10 identified genes were functionally validated in our previously established progestin-resistant cell model through Cell Counting Kit-8 (CCK-8) assays and apoptosis detection. The progestin-resistant geneand the progestin-sensitive genewere validated in vivo in xenograft mouse models. The constructed library exhibited high quality, meeting sequencing standards. Employing RRA and MLE algorithms, we identified 332 and 829 negative selection genes, as well as 3438 and 5098 positive selection genes. Enrichment analysis implicated pathways linked to DNA and RNA synthesis, metabolism, and related processes. After multiple data intersections, we identified a total of 5 genes promoting progestin resistance and 20 genes inhibiting resistance, with functional experiments confirming their roles. Employing CRISPR/Cas9 technology enables the construction of a relatively reliable network of pivotal genes associated with progestin resistance in endometrial carcinoma. Processes involving DNA and RNA synthesis, metabolism, and related mechanisms appear to significantly impact the progestin sensitivity of endometrial carcinoma. NNMT SOX17
SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1038/s41598-026-36534-x.
Key numbers
332
Negative Selection Genes
Total number of genes identified as negatively selected in the CRISPR screening.
3438
Positive Selection Genes
Total number of genes identified as positively selected in the CRISPR screening.
5
Pro-resistance Genes
Number of genes identified that promote .
Full Text
We can’t show the full text here under this license.
